Optimum treatment for young women with breast cancer needs to be determined

doi:10.1136/bmj.321.7252.53

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Richard Sainsbury, consultant surgeon (jrcs@compuserve.com),
Bob Haward, professor of cancer studies

Huddersfield Royal Infirmary, Huddersfield HD3 3EA
University of Leeds, Leeds LS2 9JT

EDITOR—The paper by Kroman et al on factors influencing the effect of age on prognosis in breast cancer has important implications for service delivery,1 increased amounts of chemotherapy being required for young women. The authors imply that only women at high risk received adjuvant chemotherapy. In all, 36.3% of their 867 patients under 35 were in the low risk group, an excess mortality being associated with not receiving chemotherapy.

We used the Yorkshire Cancer …